Value of Immunohistochemical Staining with Mutation-speciifc Antibodies in Detecting EGFR Mutations:A Meta-analysis
10.3779/j.issn.1009-3419.2014.06.03
- VernacularTitle:特异性抗体免疫组化法检测EGFR突变价值的meta分析
- Author:
MA QING
1
;
WANG JING
;
ZHONG DIANSHENG
;
NING CHAO
;
LIU CHANG
;
XIAO PING
Author Information
1. 天津医科大学总医院肿瘤科
- Keywords:
Immunohistochemistry;
DNA sequencing;
Epidermal growth factor receptor;
Meta analysis
- From:
Chinese Journal of Lung Cancer
2014;(6):451-459
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective It has been proven that epidermal growth factor receptor (EGFR) mutation is the most important predictive factor for determining the effect of EGFR tyrosine kinase inhibitors (TKIs) applied to non-small cell lung cancer (NSCLC) patients. hTe patients with EGFR mutations response better to TKIs. To detect EGFR muta-tion has been particularly essential to select ifrst-line treatment for lung cancer patients. To research and analyze the sensitivity and speciifcity of immunohistochemistry (IHC) using mutation speciifc antibodies in detecting EGFR mutations compared with DNA sequencing, and further evaluate the accuracy and clinical application value of IHC. Methods All required articles in Pubmed database were searched. hTe deadline of retrieval was March 26, 2013. hTen further screening the articles based on the inclusion and exclusion criteria. Meta analysis of diagnostic test was applied to analyze the sensitivity and speciifcity of IHC compared with DNA sequencing for the detection of EGFR mutations. Results Ten articles were included in the meta analysis, there were 1,679 samples in L858R group and 1,041 samples in E746-A750del group. hTe DOR were 225.17 (95%CI:55.67-910.69) and 267.16 (95%CI:132.45-538.88) respectively;the AUC of SROC were 0.948,4 (SEAUC=0.014,4) and 0.981,3 (SEAUC=0.009,9) respectively;the Q values were 0.888,3 (SEQ*=0.019,2) and 0.939,7 (SEQ*=0.019,1) respectively. Conclusion hTe speciifcity and sensitivity of IHC method using these two mutation-speciifc antibodies were relatively high. As a screening method for EGFR mutations, the IHC with mutation speciifc antibodies is of clinical value.
